ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
07/05/2023
Back to search
Official data from USPTO
APERTURA GENE THERAPY
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
APERTURA GENE THERAPY
ST13
US500000090803113Class
42
Filing
90803113
Registration
6987401
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
26
Latest update
08/24/2023
Trademark type
Word
Nice classes
42
Filing date
06/30/2021
Registration date
02/21/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/21/2023
Last transaction
08/24/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
04/26/2022
First use in commerce
04/26/2022
Drawing code
4
Owner type
16
Owner location
NEW YORK, NY, US
Examiner
CAYCEDO, CATHERINE ANN
Law office
L10
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
APERTURA GENE THERAPY, LLC
Deerfield Management Company, L.P.
Representatives
J. Dickson Phillips, III ROBINSON BRADSHAW & HINSON, P.A.
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Research and development in the field of gene therapy for the treatment of human and animal disease
Publications
History of USPTO decisions and trademark events.
26 publications found
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
02/21/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
02/21/2023
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
01/14/2023
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
01/13/2023
SUPC
STATEMENT OF USE PROCESSING COMPLETE
11/27/2022
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
11/27/2022
IUAF
USE AMENDMENT FILED
11/04/2022
EISU
TEAS STATEMENT OF USE RECEIVED
11/04/2022
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
06/21/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/26/2022
PUBO
PUBLISHED FOR OPPOSITION
04/26/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/06/2022
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
03/23/2022
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
03/18/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/15/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/14/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/14/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/14/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
01/11/2022
GNRT
NON-FINAL ACTION E-MAILED
01/11/2022
CNRT
NON-FINAL ACTION WRITTEN
01/11/2022
RFTP
REMOVED FROM TEAS PLUS
01/11/2022
DOCK
ASSIGNED TO EXAMINER
12/22/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/12/2021
NWAP
NEW APPLICATION ENTERED
07/03/2021
Continuous trademark protection
Get notified about every new filing that threatens APERTURA GENE THERAPY or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.